Literature DB >> 21484238

Inhibitory potencies of trimipramine and its main metabolites at human monoamine and organic cation transporters.

Britta Haenisch1, Christoph Hiemke, Heinz Bönisch.   

Abstract

RATIONALE: The antidepressant trimipramine shows an atypical pharmacological profile and its mechanism of action is still obscure.
OBJECTIVES: The present study investigated whether trimipramine and three of its metabolites interact with targets of other antidepressants, namely, the human monoamine transporters for noradrenaline (hNAT), serotonin (hSERT), and dopamine (hDAT), and with the human organic cation transporters (hOCT1, hOCT2, and hOCT3) which are expressed in the brain and are known to be involved in the uptake of monoamines.
METHODS: HEK293 cells heterologously expressing the abovementioned transporters were used to determine the inhibition of [(3)H]MPP(+) uptake by trimipramine and its main metabolites.
RESULTS: At concentrations up to 30 μM, all transporters, except hOCT3, were inhibited by all examined substances. With IC(50) values between 2 and 10 μM, trimipramine inhibited hSERT, hNAT, hOCT1, and hOCT2, whereas clearly higher concentrations were needed for half-maximal inhibition of hDAT. Desmethyl-trimipramine showed about the same potencies as trimipramine, whereas 2-hydroxy-trimipramine was less potent at hNAT, hSERT, and hOCT1. Trimipramine-N-oxide preferentially inhibited hSERT.
CONCLUSIONS: Neither trimipramine nor its metabolites are highly potent inhibitors of the examined monoamine transporters. However, since at a steady state the sum of the concentrations of the parent compound and its active metabolites is almost two times higher than the plasma concentration of trimipramine and since it is known that tricyclic antidepressants accumulate in the brain (up to tenfold), at least partial inhibition by trimipramine and its metabolites of hSERT and hNAT (but not of hOCT3) may contribute to the antidepressant action of trimipramine.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21484238     DOI: 10.1007/s00213-011-2281-9

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  32 in total

1.  Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro.

Authors:  E Richelson; A Nelson
Journal:  J Pharmacol Exp Ther       Date:  1984-07       Impact factor: 4.030

2.  Monoamine neurotransmitter transport mediated by the polyspecific cation transporter rOCT1.

Authors:  A E Busch; S Quester; J C Ulzheimer; V Gorboulev; A Akhoundova; S Waldegger; F Lang; H Koepsell
Journal:  FEBS Lett       Date:  1996-10-21       Impact factor: 4.124

3.  Steady state concentrations of clomipramine and its major metabolite desmethylclomipramine in rat brain and serum after oral administration of clomipramine.

Authors:  H Weigmann; S Härtter; M Bagli; C Hiemke
Journal:  Eur Neuropsychopharmacol       Date:  2000-09       Impact factor: 4.600

4.  Trimipramine--an atypical neuroleptic?

Authors:  G Eikmeier; M Berger; E Lodemann; K Muszynski; S Kaumeier; M Gastpar
Journal:  Int Clin Psychopharmacol       Date:  1991       Impact factor: 1.659

5.  The sleep EEG and nocturnal hormonal secretion studies on changes during the course of depression and on effects of CNS-active drugs.

Authors:  A Steiger; U von Bardeleben; J Guldner; C Lauer; B Rothe; F Holsboer
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  1993-01       Impact factor: 5.067

6.  Organic cation transporter 3: Keeping the brake on extracellular serotonin in serotonin-transporter-deficient mice.

Authors:  Nicole L Baganz; Rebecca E Horton; Alfredo S Calderon; W Anthony Owens; Jaclyn L Munn; Lora T Watts; Nina Koldzic-Zivanovic; Nathaniel A Jeske; Wouter Koek; Glenn M Toney; Lynette C Daws
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-24       Impact factor: 11.205

7.  Outcome in delusional depression comparing trimipramine monotherapy with a combination of amitriptyline and haloperidol--a double-blind multicenter trial.

Authors:  Heike E Künzel; Nibal Ackl; Martin Hatzinger; Katja Held; Edith Holsboer-Trachsler; Marcus Ising; Wolfgang Kaschka; Siegfried Kasper; Anastasios Konstantinidis; Annette Sonntag; Manfred Uhr; Alexander Yassouridis; Florian Holsboer; Axel Steiger
Journal:  J Psychiatr Res       Date:  2008-11-26       Impact factor: 4.791

8.  Trimipramine, a tricyclic antidepressant exerting atypical actions on the central noradrenergic system.

Authors:  K Hauser; H R Olpe; R S Jones
Journal:  Eur J Pharmacol       Date:  1985-04-23       Impact factor: 4.432

9.  High-dose trimipramine in acute schizophrenia. Preliminary results of an open trial.

Authors:  G Eikmeier; K Muszynski; M Berger; M Gastpar
Journal:  Pharmacopsychiatry       Date:  1990-09       Impact factor: 5.788

10.  Effects of polymorphisms in CYP2D6, CYP2C9, and CYP2C19 on trimipramine pharmacokinetics.

Authors:  Julia Kirchheiner; Gunnar Müller; Ingolf Meineke; Klaus-Dieter Wernecke; Ivar Roots; Jürgen Brockmöller
Journal:  J Clin Psychopharmacol       Date:  2003-10       Impact factor: 3.153

View more
  4 in total

1.  Interaction of antidepressant and antipsychotic drugs with the human organic cation transporters hOCT1, hOCT2 and hOCT3.

Authors:  Britta Haenisch; Eva Drescher; Lidia Thiemer; Hu Xin; Bruno Giros; Sophie Gautron; Heinz Bönisch
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-07-18       Impact factor: 3.000

2.  An in vivo drug repurposing screen and transcriptional analyses reveals the serotonin pathway and GSK3 as major therapeutic targets for NGLY1 deficiency.

Authors:  Kevin A Hope; Alexys R Berman; Randall T Peterson; Clement Y Chow
Journal:  PLoS Genet       Date:  2022-06-02       Impact factor: 6.020

3.  Substrate-Dependent Inhibition of the Human Organic Cation Transporter OCT2: A Comparison of Metformin with Experimental Substrates.

Authors:  Kristina Hacker; Renke Maas; Johannes Kornhuber; Martin F Fromm; Oliver Zolk
Journal:  PLoS One       Date:  2015-09-01       Impact factor: 3.240

Review 4.  Active metabolites as antidepressant drugs: the role of norquetiapine in the mechanism of action of quetiapine in the treatment of mood disorders.

Authors:  Francisco López-Muñoz; Cecilio Alamo
Journal:  Front Psychiatry       Date:  2013-09-12       Impact factor: 4.157

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.